Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy

doi:10.4239/wjd.v17.i2.112867

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (90)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-2)

Tables (1-6)

Sum=28

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=49

Feb 15, 2026 (publication date) through Feb 12, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Feb 15, 2026; 17(2): 112867
Published online Feb 15, 2026. doi: 10.4239/wjd.v17.i2.112867

Open in New Tab Full Size Figure Download Figure

Figure 1 Comparison of blood glucose levels between two groups of patients before and after treatment. A: Fasting plasma glucose (mg/dL); B: Hemoglobin A1c (%). FPG: Fasting plasma glucose; HbA1c: Hemoglobin A1c; CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparison of clinical efficacy between two groups of patients. CM: Canagliflozin monotherapy; CSCT: Canagliflozin and semaglutide combination therapy.

Citation: Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM. Renal and metabolic effects of semaglutide plus canagliflozin vs canagliflozin alone in type 2 diabetic nephropathy. World J Diabetes 2026; 17(2): 112867
URL: https://www.wjgnet.com/1948-9358/full/v17/i2/112867.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i2.112867